Uric acid: A cardiovascular risk factor in patients with recent myocardial infarction

International Journal of Cardiology

Volumn 167, Issue 1, 2013, Pages 262-269

  Levantesi, Giacomo ^a   Marfisi, Rosa Maria ^a   Franzosi, Maria Grazia ^b   Maggioni, Aldo Pietro ^c   Nicolosi, Gian Luigi ^d   Schweiger, Carlo ^e   Silletta, Maria Giuseppina ^a   Tavazzi, Luigi ^f   Tognoni, Gianni ^a   Marchioli, Roberto ^a  

^a Consorzio Mario Negri Sud ^*  (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c ANMCO RESEARCH CENTER   (Italy)

^d Cardiology Unit   (Italy)

^e OC Passirana di Rho   (Italy)

^f Research Ettore Sansavini Health Science Foundation   (Italy)

Author keywords

Cardiovascular diseases; Coronary disease; Prevention; Risk factors

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; OMEGA 3 ACID ETHYL ESTER; URIC ACID;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; RISK ASSESSMENT; URIC ACID BLOOD LEVEL;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RISK FACTORS; TIME FACTORS; URIC ACID;

EID: 84878594838     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.12.110     Document Type: Article

References (69)

1. F. Mahomed On chronic Bright's disease, and its essential symptoms Lancet 113 2899 1879 399 401
2. K. Masuo, H. Kawaguchi, H. Mikami, T. Ogihara, and M.L. Tuck Serum uric acid and plasma norepinephrine concentrations predict subsequent weight gain and blood pressure elevation Hypertension 42 4 2003 474 480
3. J.P. Forman, H. Choi, and G.C. Curhan Plasma uric acid level and risk for incident hypertension among men J Am Soc Nephrol 18 1 2007 287 292
4. A. Shankar, R. Klein, B.E. Klein, and F.J. Nieto The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study J Hum Hypertens 20 12 2006 937 945
5. N. Nakanishi, M. Okamoto, H. Yoshida, Y. Matsuo, K. Suzuki, and K. Tatara Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers Eur J Epidemiol 18 6 2003 523 530
6. L. Niskanen, D.E. Laaksonen, and J. Lindstrom Serum uric acid as a harbinger of metabolic outcome in subjects with impaired glucose tolerance: the Finnish Diabetes Prevention Study Diabetes Care 29 3 2006 709 711
7. K.M. Talaat, and A.R. el-Sheikh The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease Am J Nephrol 27 5 2007 435 440
8. M.H. Alderman, H. Cohen, S. Madhavan, and S. Kivlighn Serum uric acid and cardiovascular events in successfully treated hypertensive patients Hypertension 34 1 1999 144 150
9. J. Fang, and M.H. Alderman Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. National Health and Nutrition Examination Survey JAMA 283 18 2000 2404 2410
10. L.K. Niskanen, D.E. Laaksonen, and K. Nyyssonen Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study Arch Intern Med 164 14 2004 1546 1551
11. D.I. Feig, and R.J. Johnson Hyperuricemia in childhood primary hypertension Hypertension 42 3 2003 247 252
12. T. Nakagawa, K.R. Tuttle, R.A. Short, and R.J. Johnson Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome Nat Clin Pract Nephrol 1 2 2005 80 86
13. A.D. Liese, H.W. Hense, H. Lowel, A. Doring, M. Tietze, and U. Keil Association of serum uric acid with all-cause and cardiovascular disease mortality and incident myocardial infarction in the MONICA Augsburg cohort. World Health Organization Monitoring Trends and Determinants in Cardiovascular Diseases Epidemiology 10 4 1999 391 397
14. P. Verdecchia, G. Schillaci, G. Reboldi, F. Santeusanio, C. Porcellati, and P. Brunetti Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study Hypertension 36 6 2000 1072 1078
15. E. Krishnan, J.F. Baker, D.E. Furst, and H.R. Schumacher Gout and the risk of acute myocardial infarction Arthritis Rheum 54 8 2006 2688 2696
16. M.J. Bos, P.J. Koudstaal, A. Hofman, J.C. Witteman, and M.M. Breteler Uric acid is a risk factor for myocardial infarction and stroke: the Rotterdam study Stroke 37 6 2006 1503 1507
17. A. Hozawa, A.R. Folsom, H. Ibrahim, F. Javier Nieto, W.D. Rosamond, and E. Shahar Serum uric acid and risk of ischemic stroke: the ARIC Study Atherosclerosis 187 2 2006 401 407
18. H.K. Choi, and G. Curhan Independent impact of gout on mortality and risk for coronary heart disease Circulation 116 8 2007 894 900
19. B.F. Culleton, M.G. Larson, W.B. Kannel, and D. Levy Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study Ann Intern Med 131 1 1999 7 13
20. J.T. Moriarity, A.R. Folsom, C. Iribarren, F.J. Nieto, and W.D. Rosamond Serum uric acid and risk of coronary heart disease: Atherosclerosis Risk in Communities (ARIC) Study Ann Epidemiol 10 3 2000 136 143
21. A.G. Ioachimescu, D.M. Brennan, B.M. Hoar, S.L. Hazen, and B.J. Hoogwerf Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a preventive cardiology information system (PreCIS) database cohort study Arthritis Rheum 58 2 2008 623 630
22. S.C. Smith Jr., J. Allen, and S.N. Blair AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute J Am Coll Cardiol 47 10 2006 2130 2139
23. I. Graham, D. Atar, and K. Borch-Johnsen European guidelines on cardiovascular disease prevention in clinical practice: executive summary Eur Heart J 28 19 2007 2375 2414
24. Protocol of the GISSI-prevention study. Study of preventive intervention in the atherosclerotic and thrombotic components of post-infarction risk G Ital Cardiol 23 10 1993 1053 1061
25. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Lancet 354 9177 1999 447 455
26. R. Marchioli, F. Barzi, and E. Bomba Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione Circulation 105 16 2002 1897 1903
27. D. Mozaffarian, R. Marfisi, and G. Levantesi Incidence of new-onset diabetes and impaired fasting glucose in patients with recent myocardial infarction and the effect of clinical and lifestyle risk factors Lancet 370 9588 2007 667 675
28. J.A. Hanley, and B.J. McNeil The meaning and use of the area under a receiver operating characteristic (ROC) curve Radiology 143 1 1982 29 36
29. M.J. Pencina, R.B. D'Agostino Sr., R.B. D'Agostino Jr., and R.S. Vasan Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond Stat Med 27 2 2008 157 172 [discussion 207-112]
30. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 19 2001 2486 2497
31. P. Greenland, S.C. Smith Jr., and S.M. Grundy Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests Circulation 104 15 2001 1863 1867
32. T.E. Madsen, J.B. Muhlestein, and J.F. Carlquist Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease Am J Nephrol 25 1 2005 45 49
33. A.B. Alper Jr., W. Chen, L. Yau, S.R. Srinivasan, G.S. Berenson, and L.L. Hamm Childhood uric acid predicts adult blood pressure: the Bogalusa Heart Study Hypertension 45 1 2005 34 38
34. E. Krishnan, C.K. Kwoh, H.R. Schumacher, and L. Kuller Hyperuricemia and incidence of hypertension among men without metabolic syndrome Hypertension 49 2 2007 298 303
35. P.B. Mellen, A.J. Bleyer, and T.P. Erlinger Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study Hypertension 48 6 2006 1037 1042
36. K. Nagahama, T. Inoue, and K. Iseki Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan Hypertens Res 27 11 2004 835 841
37. T.S. Perlstein, O. Gumieniak, and G.H. Williams Uric acid and the development of hypertension: the normative aging study Hypertension 48 6 2006 1031 1036
38. J. Sundstrom, L. Sullivan, R.B. D'Agostino, D. Levy, W.B. Kannel, and R.S. Vasan Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence Hypertension 45 1 2005 28 33
39. F.N. Brand, D.L. McGee, W.B. Kannel, J. Stokes III, and W.P. Castelli Hyperuricemia as a risk factor of coronary heart disease: the Framingham Study Am J Epidemiol 121 1 1985 11 18
40. M. Mazzali, J. Hughes, and Y.G. Kim Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism Hypertension 38 5 2001 1101 1106
41. M. Mazzali, J. Kanellis, and L. Han Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism Am J Physiol Renal Physiol 282 6 2002 F991 F997
42. U.M. Khosla, S. Zharikov, and J.L. Finch Hyperuricemia induces endothelial dysfunction Kidney Int 67 5 2005 1739 1742
43. I. Saito, T. Saruta, and K. Kondo Serum uric acid and the renin-angiotensin system in hypertension J Am Geriatr Soc 26 6 1978 241 247
44. W. Doehner, N. Schoene, and M. Rauchhaus Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies Circulation 105 22 2002 2619 2624
45. C.A. Farquharson, R. Butler, A. Hill, J.J. Belch, and A.D. Struthers Allopurinol improves endothelial dysfunction in chronic heart failure Circulation 106 2 2002 221 226
46. G. Mercuro, C. Vitale, and E. Cerquetani Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk Am J Cardiol 94 7 2004 932 935
47. D.H. Kang, S.K. Park, I.K. Lee, and R.J. Johnson Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells J Am Soc Nephrol 16 12 2005 3553 3562
48. D.B. Corry, P. Eslami, K. Yamamoto, M.D. Nyby, H. Makino, and M.L. Tuck Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system J Hypertens 26 2 2008 269 275
49. M. Frohlich, A. Imhof, and G. Berg Association between C-reactive protein and features of the metabolic syndrome: a population-based study Diabetes Care 23 12 2000 1835 1839
50. C. Ruggiero, A. Cherubini, and A. Ble Uric acid and inflammatory markers Eur Heart J 27 10 2006 1174 1181
51. C. Ruggiero, A. Cherubini, and E. Miller III Usefulness of uric acid to predict changes in C-reactive protein and interleukin-6 in 3-year period in Italians aged 21 to 98 years Am J Cardiol 100 1 2007 115 121
52. P. Duewell, H. Kono, and K.J. Rayner NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals Nature 464 7293 2010 1357 1361
53. F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, and J. Tschopp Gout-associated uric acid crystals activate the NALP3 inflammasome Nature 440 7081 2006 237 241
54. B.K. Davis, H. Wen, and J.P. Ting The inflammasome NLRs in immunity, inflammation, and associated diseases Annu Rev Immunol 29 2011 707 735
55. D.J. Schretlen, A.B. Inscore, and T.D. Vannorsdall Serum uric acid and brain ischemia in normal elderly adults Neurology 69 14 2007 1418 1423
56. S.G. Wannamethee, A.G. Shaper, and P.H. Whincup Serum urate and the risk of major coronary heart disease events Heart 78 2 1997 147 153
57. T. Nakagawa, H. Hu, and S. Zharikov A causal role for uric acid in fructose-induced metabolic syndrome Am J Physiol Renal Physiol 290 3 2006 F625 F631
58. L.G. Sanchez-Lozada, E. Tapia, and P. Bautista-Garcia Effects of febuxostat on metabolic and renal alterations in rats with fructose-induced metabolic syndrome Am J Physiol Renal Physiol 294 4 2008 F710 F718
59. S. Reungjui, C.A. Roncal, and W. Mu Thiazide diuretics exacerbate fructose-induced metabolic syndrome J Am Soc Nephrol 18 10 2007 2724 2731
60. S. Furukawa, T. Fujita, and M. Shimabukuro Increased oxidative stress in obesity and its impact on metabolic syndrome J Clin Invest 114 12 2004 1752 1761
61. Y.Y. Sautin, T. Nakagawa, S. Zharikov, and R.J. Johnson Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress Am J Physiol Cell Physiol 293 2 2007 C584 C596
62. M.R. Hayden, and S.C. Tyagi Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle Nutr Metab (Lond) 1 1 2004 10
63. M.A. Hlatky, P. Greenland, and D.K. Arnett Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association Circulation 119 17 2009 2408 2416
64. D.I. Feig, B. Soletsky, and R.J. Johnson Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial JAMA 300 8 2008 924 932
65. M. Kanbay, A. Ozkara, and Y. Selcoki Effect of treatment of hyperuricemia with allopurinol on blood pressure, creatinine clearance, and proteinuria in patients with normal renal functions Int Urol Nephrol 39 4 2007 1227 1233
66. Y.P. Siu, K.T. Leung, M.K. Tong, and T.H. Kwan Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level Am J Kidney Dis 47 1 2006 51 59
67. J. Dawson, and M. Walters Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol 62 6 2006 633 644
68. A. Hoieggen, M.H. Alderman, and S.E. Kjeldsen The impact of serum uric acid on cardiovascular outcomes in the LIFE study Kidney Int 65 3 2004 1041 1049
69. V.G. Athyros, M. Elisaf, and A.A. Papageorgiou Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart- disease Evaluation (GREACE) study Am J Kidney Dis 43 4 2004 589 599